Effective March 19, 2025, ChromaDex Corporation has officially changed its name to Niagen Bioscience, Inc., reflecting our sharpened focus on pioneering NAD+ science and our flagship ingredient Niagen®. In conjunction with this corporate rebranding, our NASDAQ ticker symbol will change from "CDXC" to "NAGE" at market open on March 19, 2025.
The company's shares will continue trading on the NASDAQ Capital Market under the new ticker symbol "NAGE." No action is required by current shareholders, as outstanding stock certificates remain valid and will not need to be exchanged.
While adopting the Niagen Bioscience identity, the company will continue to provide gold standard reference standards services. This strategic rebranding aligns our corporate identity with our scientific leadership in NAD+ research and our commitment to advancing cellular health innovations.
Niagen Bioscience, led by world-renowned scientists working with global research institutions, pioneers research on nicotinamide adenine dinucleotide (NAD+). This essential coenzyme, present in all living cells, is fundamental to mitochondrial bioenergetics, metabolic homeostasis, and genomic stability. Research shows NAD+ levels decline with age and stress, correlating with diminished cellular function and physiological resilience.
Distinguished by uncompromising scientific standards, the company has developed patented Niagen® (nicotinamide riboside, NR), which demonstrates superior efficacy compared to other NAD+ precursors in clinical trials. This proprietary compound powers evidence-based NAD+ enhancement solutions available in both forms: pharmaceutical-grade intravenous and injectable formulations under Niagen Plus, and high-bioavailability oral supplements like Tru Niagen. Our comprehensive intellectual property portfolio safeguards these innovations while we continue to advance the scientific understanding of NAD+ metabolism and its implications for human health.